Evaluation of the effect of GCSF injection in treatment of COVID-19 patients with lymphopenia

Evaluation of the effect of GCSF injection in treatment of COVID-19 patients with lymphopenia (less than 1000)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200502047268N1

Enrollment

Registered

2020-05-16

Start date

2020-05-21

Completion date

Unknown

Last updated

2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid-19. Coronavirus infection, unspecified

Interventions

Intervention 1: Intervention group: Granulocyte colony-stimulating factor (GCSF) stimulant dose is administered to patients as an intravenous dose. Then a blood test is done one day and 3 days after t

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: COVID-19 pneumonia Conscious consent of the patient

Exclusion criteria

Exclusion criteria: Without lymphopenia

Design outcomes

Primary

Measure	Time frame
Blood lymphocytes. Timepoint: Befor entering the study and 3 days after drug injection. Method of measurement: Using hemocytometer.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmir Sarabi

Semnan University of Medical Sciences

drsam_amir@yahoo.com+98 23 3344 0022

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026